REG-Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
Globe Newswire•30/10/2026•03:00 ET
0
Key Highlights
- ➤Q3 2026 results scheduled for November 5, 2026
- ➤Updated cash runway guidance will accompany third-quarter results
- ➤Vivoryon targets funding to advance varoglutamstat into Phase 2b
- ➤Advanced partnership negotiations underway for varoglutamstat in kidney disease
- ➤Additional cost-saving measures implemented to preserve financial resources
Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026
Halle (Saale) / Munich, Germany, October 30, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that it will publish its third quarter financial results for the period ended September 30, 2026 on Thursday, November 5, 2026.
Get started
Create a free account to read the full story.